Financials data is unavailable for this security.
View more
Year on year Lionco Pharmaceutical Group Co Ltd had revenues fall -31.95% from 289.26m to 196.83m, though the company grew net income from a loss of 195.86m to a smaller loss of 151.50m.
| Gross margin | 41.77% |
|---|---|
| Net profit margin | -36.73% |
| Operating margin | -38.96% |
| Return on assets | -6.77% |
|---|---|
| Return on equity | -10.77% |
| Return on investment | -7.85% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Lionco Pharmaceutical Group Co Ltd fell by 248.76m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 37.87m. In addition the company used 51.90m on investing activities and also paid 158.99m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1.19 |
|---|---|
| Tangible book value per share | 1.04 |
More ▼
Balance sheet in CNYView more
| Current ratio | 5.64 |
|---|---|
| Quick ratio | 4.94 |
| Total debt/total equity | 0.3173 |
|---|---|
| Total debt/total capital | 0.2409 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 22.22%.
| Div yield(5 year avg) | 1.67% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 51.67 |
More ▼
